| Literature DB >> 31761885 |
Takashi Ishiguro1, Ryuji Uozumi2, Hiroaki Yoshioka3, Takashi Nishida1, Noboru Takayanagi1.
Abstract
Objective In Japan, the aging demographic structure is becoming pronounced, and the full-blown graying of society appears not far off, which indicates an increasing population that will require healthcare contact. Klebsiella spp. are major pathogens in healthcare-associated infections, and their importance is increasing. The aim of this study was to clarify the characteristics of Klebsiella spp. chest infections by evaluating the differences in the characteristics of chest infections caused by Klebsiella spp. and pneumoniae. Methods We conducted a retrospective study of consecutive patients hospitalized with pneumonia, lung abscess/necrotizing pneumonia, and empyema due to Klebsiella spp. and S. pneumoniae for 15 years at our institution in Saitama, Japan. Patients Patients with chest infections due to Klebsiella spp. (K group, n=76) and S. pneumoniae (S group, n=446) were included. Results The K group more frequently was male, older, coinfected by Pseudomonas aeruginosa, and had diabetes mellitus, a history of upper digestive system surgery, alcohol drinking habit, a smoking habit, and an impaired premorbid performance status than the S group. The percentages of lung abscesses or necrotizing pneumonia (31.6% vs. 0.9%) and empyema without pulmonary parenchymal shadow (3.9% vs. 0.7%) were higher in the K group than those in the S group. Severity on admission and mortality did not differ between the groups; however, patients in the K group required a longer duration of antibiotics administration and hospital stay than those in the S group. Conclusion Klebsiella spp. chest infections have some marked characteristics when compared with pneumococcal infections, and our results serve to differentiate Klebsiella spp. infection from pneumococcal infection.Entities:
Keywords: Klebsiella pneumoniae; Streptococcus pneumoniae; lung abscess; necrotizing pneumonia; pulmonary gangrene
Mesh:
Year: 2019 PMID: 31761885 PMCID: PMC7086319 DOI: 10.2169/internalmedicine.3531-19
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Patient Characteristics, Laboratory Data, and Outcomes.
| Characteristic | Pneumococcal infection (n=446) | p value | ||||
|---|---|---|---|---|---|---|
| Infection type | ||||||
| Pneumonia | 45 (59.2%) | 436 (97.8%) | <0.0001 | |||
| Lung abscess/necrotizing pneumonia | 24 (31.6%) | 4 (0.9%) | <0.0001 | |||
| Pneumonia plus empyema | 2 (2.6%) | 2 (0.4%) | 0.1032 | |||
| Lung abscess/necrotizing pneumonia plus empyema | 2 (2.6%) | 1 (0.2%) | 0.0569 | |||
| Empyema | 3 (3.9%) | 3 (0.7%) | 0.0428 | |||
| Sex, male | 66 (86.8%) | 308 (69.1%) | 0.0014 | |||
| Age, mean years (standard deviation) | 72.3 (10.95) | 68.8 (13.90) | 0.0337 | |||
| Vaccine history, yes | ||||||
| PPV | 2 (2.6%) | 20 (4.5%) | 0.7561 | |||
| Influenza | 3 (3.9%) | 29 (6.5%) | 0.6035 | |||
| Smoking status, current smokers | 61 (80.3%) | 283 (63.5%) | 0.0039 | |||
| Alcohol habit, Heavy drinking/Usual/Slight or no drinking | 10/18/5 | 8/27/411 | <0.0001 | |||
| LTOT | 5 (6.6%) | 35 (7.8%) | 0.8192 | |||
| Premorbid PS, 0/1-2/3-4 | 27/25/11 | 240/114/34 | 0.0158 | |||
| Type of pneumonia, CAP | 47 (61.8%) | 303 (67.9%) | 0.2943 | |||
| Underlying diseases, yes | ||||||
| COPD | 15 (19.7%) | 106 (23.8%) | 0.5563 | |||
| Bronchiectasis | 6 (7.9%) | 20 (4.5%) | 0.2475 | |||
| Pulmonary non-tuberculous mycobacteria | 7 (9.2%) | 19 (4.3%) | 0.0831 | |||
| Old tuberculosis | 4 (5.3%) | 22 (4.9%) | 0.7814 | |||
| Chronic pulmonary aspergillosis | 0 (0.0%) | 7 (1.6%) | 0.6009 | |||
| Interstitial pneumonia | 3 (3.9%) | 31 (7.0%) | 0.4528 | |||
| History of lung cancer surgery | 3 (3.9%) | 11 (2.5%) | 0.4407 | |||
| Pneumoconiosis | 0 (0.0%) | 7 (1.6%) | 0.6009 | |||
| Other pulmonary diseases | 3 (3.9%) | 4 (0.9%) | 0.0671 | |||
| Hypertension | 11 (14.5%) | 45 (10.1%) | 0.3138 | |||
| Congestive heart failure | 4 (5.3%) | 26 (5.8%) | 1.0000 | |||
| Ischemic heart disease | 1 (1.3%) | 21 (4.7%) | 0.2279 | |||
| Diabetes mellitus | 20 (26.3%) | 47 (10.5%) | 0.0006 | |||
| Cerebral vascular disease | 4 (5.3%) | 32 (7.2%) | 0.8058 | |||
| Dementia | 2 (2.6%) | 4 (0.9%) | 0.2126 | |||
| Neuromuscular disease | 4 (5.3%) | 5 (1.1%) | 0.0295 | |||
| History of upper digestive system surgery | 7 (9.2%) | 14 (3.1%) | 0.0222 | |||
| Chronic liver disease | 2 (2.6%) | 12 (2.7%) | 1.0000 | |||
| Connective tissue diseases | 4 (5.3%) | 14 (3.1%) | 0.3150 | |||
| Steroid or immunosuppressant | 3 (3.9%) | 27 (6.1%) | 0.6006 | |||
| Malignant disease | 1 (1.3%) | 13 (2.9%) | 0.7041 | |||
| CKD | 2 (2.6%) | 8 (1.8%) | 0.6448 | |||
| None | 9 (11.8%) | 94 (21.1%) | 0.0628 | |||
| Blood tests, median (range) [number measured] | ||||||
| WBC (/mm3) | 10,600.0 (1,300-240) [76] | 11,300.0 (600-47,100) [446] | 0.1170 | |||
| Platelets (×104/mm3) | 26.9 (0.8-64.8) [62] | 22.9 (4.8-86.8) [117] | 0.0068 | |||
| AST (IU/L) | 24.0 (7-514) [75] | 25.0 (9-431) [442] | 0.3553 | |||
| LDH (IU/L) | 208.0 (41-978) [76] | 218.0 (17-923) [437] | 0.8215 | |||
| CK (IU/L) | 76.5 (13-1,384) [58] | 73.0 (7-20,485) [400] | 0.4981 | |||
| BUN (mg/dL) | 16.0 (7-123) [65] | 18.0 (5-98) [437] | 0.5943 | |||
| Creatinine (mg/dL) | 0.7 (0.3-2.4) [65] | 0.7 (0.3-3.4) [440] | 0.9052 | |||
| Na (mmol/L) | 138.0 (127-153) [60] | 137.0 (116-148) [143] | 0.1019 | |||
| CRP (mg/dL) | 13.3 (0.8-54.6) [65] | 13.5 (0.09-54.3) [445] | 0.6862 | |||
| Duration, days, mean±standard deviation | ||||||
| Antibiotic administration | 13.3±6.2 | 9.5±4.6 | <.0001 | |||
| Hospital stay | 22.6±19.7 | 17.0±19.2 | 0.0179 | |||
| Hospital mortality | 5 (6.6%) | 22 (4.9%) | 0.5731 |
PPV: pneumococcal polysaccharide vaccine, LTOT: long-term oxygen therapy, PS: performance status, CAP: community-acquired pneumonia, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, WBC: white blood cell count (/mm3), AST: aspartate transaminase, LDH: lactate dehydrogenase, CK: creatine kinase, BUN: blood urea nitrogen, CRP: C-reactive protein
Diagnostic Methods and Results of the Patients in the Present Study (n=522).
| Method | No. of samples studied | No. of positive diagnostic studies (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall pathogens | Pneumococcal infection | |||||||
| Paired sera | 343 | 36 (10.5) | 4 (10.8) | 32 (10.5) | ||||
| Rapid influenza diagnostic test | 497 | 41 (8.2) | 4 (7.1) | 36 (8.3) | ||||
| Urinary antigen | 484 | 394 (81.4) | 1 (2.0) | 386 (90.4) | ||||
| Culture | ||||||||
| Sputum | 477 | 215 (45.0) | 53 (89.8) | 157 (39.3) | ||||
| Transbronchial aspirate | 23 | 9 (39.1) | 6 (60.0) | 3 (25.0) | ||||
| Protected specimen brush | 15 | 13 (86.7) | 12 (100) | 1 (33.3) | ||||
| Bronchial washing | 18 | 12 (66.7) | 7 (77.8) | 5 (62.5) | ||||
| Bronchoalveolar lavage fluid | 7 | 3 (42.9) | 1 (14.3) | 2 (33.3) | ||||
| Blood | 340 | 26 (7.6) | 4 (9.8) | 22 (7.4) | ||||
| Pleural fluid | 18 | 9 (50.0) | 4 (66.7) | 4 (36.4) | ||||
Etiologies of Mixed Infection.
| Species | Pneumococcal infection | p value | ||||
|---|---|---|---|---|---|---|
| Mixed infection | 19 (25.0%) | 104 (23.3%) | 0.7704 | |||
| 1 (1.3%) | 17 (3.8%) | 0.4934 | ||||
| 0 (0.0%) | 6 (1.3%) | 0.5997 | ||||
| Influenza virus | 4 (5.3%) | 53 (11.9%) | 0.1101 | |||
| 6 (7.9%) | 2 (0.4%) | 0.0002 | ||||
| 0 (0.0%) | 5 (1.1%) | 1.0000 | ||||
| Enterobacteriaceae other than | 1 (1.3%) | 1 (0.2%) | 0.2702 | |||
| 2 (2.6%) | 1 (0.2%) | 0.0569 | ||||
| 2 (2.6%) | 16 (3.6%) | 1.0000 | ||||
| 1 (1.3%) | 1 (0.2%) | 0.2702 | ||||
| MSSA | 1 (1.3%) | 5 (1.1%) | 1.0000 | |||
| Others | 1 (1.3%) | 1 (0.2%) | 0.2702 |
MSSA: methicillin-sensitive Staphylococcus aureus
Antibacterial Susceptibility of Isolated Klebsiella species.
| Number tested | Susceptible | (%) | ||||
|---|---|---|---|---|---|---|
| ABPC | 50 | 0 | 0 | |||
| AMPC/CVA | 16 | 14 | 87.5 | |||
| ABPC/SBT | 28 | 26 | 92.9 | |||
| PIPC | 56 | 29 | 51.8 | |||
| PIPC/TAZ | 9 | 7 | 77.8 | |||
| CAZ | 57 | 56 | 98.2 | |||
| CEZ | 56 | 56 | 100 | |||
| CMZ | 55 | 55 | 100 | |||
| CTRX | 12 | 12 | 100 | |||
| CFPM | 28 | 28 | 100 | |||
| IPM | 56 | 56 | 100 | |||
| MEPM | 26 | 26 | 100 | |||
| GM | 58 | 58 | 100 | |||
| AMK | 58 | 57 | 98.3 | |||
| LVFX | 26 | 26 | 100 | |||
| CPFX | 28 | 27 | 96.4 | |||
| MINO | 57 | 54 | 94.7 | |||
| AZT | 58 | 48 | 85.8 |
ABPC: ampicillin, AMPC: amoxicillin, CVA: clavulanic acid, SBT: sulbactam, PIPC: piperacillin, TAZ: tazobactam, CAZ: ceftazidime, CEZ: cefazolin, CMZ: cefmetazole, CTRX: ceftriaxone, CFPM: cefepime, IPM: imipenem, MEPM: meropenem, GM: gentamicin, AMK: amikacin, LVFX: levofloxacin, CPFX: ciprofloxacin, MINO: minocycline, AZT: aztreonam
Figure.Images from chest X-ray and computed tomography (CT) performed at the local hospital of a 64-year-old man with a history of hypertension showed bilateral consolidation (a-c). On the 10th day after referral to our hospital (7th hospital day at our institution), CT showed bilateral consolidation with a hyperlucent area (d), and consolidation was replaced by cavitary lesions (e).
Treatment and Outcomes.
| Pneumococcal infection (n=446) | p value | ||
|---|---|---|---|
| Mechanical ventilation | 7 (9.2%) | 19 (4.3%) | 0.0831 |
| Initial antibiotics | |||
| Carbapenems, 3rd- or 4th-generation cephalosporins plus macrolides | 3 (3.9%) | 62 (13.9%) | 0.0135 |
| Carbapenems, 3rd- or 4th-generation cephalosporins plus fluoroquinolones | 1 (1.3%) | 9 (2.0%) | 1.0000 |
| Carbapenems, 3rd- or 4th-generation cephalosporins plus minocyclines | 1 (1.3%) | 2 (0.4%) | 0.3769 |
| Single carbapenems, 3rd- or 4th-generation cephalosporins | 9 (11.8%) | 41 (9.2%) | 0.5255 |
| Penicillins plus macrolides | 0 (0%) | 2 (0.4%) | 1.0000 |
| Single penicillins | 4 (5.3%) | 4 (0.9%) | 0.0184 |
| Penicillins combined with β-lactamase inhibitors | 27 (35.5%) | 109 (24.4%) | 0.0480 |
| Penicillins combined with β-lactamase inhibitors plus macrolides | 27 (35.5%) | 179 (40.1%) | 0.5258 |
| Penicillins combined with β-lactamase inhibitors plus fluoroquinolones | 1 (1.3%) | 13 (2.9%) | 0.7041 |
| Penicillins combined with β-lactamase inhibitors plus minocyclines | 1 (1.3%) | 3 (0.7%) | 0.4681 |
| Others | 1 (1.3%) | 5 (1.1%) | 1.0000 |
| Number of antibiotics for initial treatment | |||
| Single drug | 40 (52.66%) | 171 (38.3%) | 0.0227 |
| ≥2 drugs | 36 (47.4%) | 275 (61.7%) |